Every day of enrollment delay costs your program
Time-critical enrollment, biomarker complexity, and multi-line therapy history make oncology trials among the hardest to fill. TrialScreen handles the screening burden so your CRCs focus on patients who qualify.
See How It Works →Why oncology enrollment falls behind
Oncology trials face unique pressures that traditional screening can't keep up with.
Time-Critical Enrollment Windows
Oncology patients often have narrow treatment windows. A week of enrollment delay can mean a patient progresses past eligibility or starts an alternative therapy that excludes them.
Biomarker Complexity
Mutation-specific protocols require matching on EGFR, ALK, KRAS, HER2, BRCA, and dozens of other biomarkers. Manual screening struggles to track which mutations qualify for which trials.
Multi-Line Therapy History
Protocols specify prior lines of therapy, washout periods, and specific regimen combinations. Tracking a patient’s full treatment history against these criteria is error-prone by hand.
How TrialScreen accelerates oncology enrollment
Protocol Intelligence for Biomarkers
TrialScreen parses biomarker criteria directly from your protocol. When a participant reports their mutation status, the system matches against every eligible trial in your portfolio automatically.
Portfolio Matching Across Mutations
A patient who doesn’t qualify for a KRAS G12C trial may match an EGFR or ALK study. TrialScreen evaluates every active oncology protocol in a single screening interaction.
Image Analysis for Lab Results
Patients text photos of lab reports and pathology results. TrialScreen extracts biomarker status, tumor markers, and staging data from images and maps them to protocol criteria.
The cost of slow enrollment
cost per screen failure
JCO, 2016
average trials managed by oncology CRCs
ACRP, 2020
per day lost to enrollment delays
Tufts CSDD
See how TrialScreen handles oncology protocols
Book a demo and we'll run a live screening session against your oncology protocol — biomarker criteria included.